KDM1A and neoplasm: Regardless, our results substantiate that such targeting can offer possible anti-tumor efficacy in malignancies that are especially sensitive to LSD1 inhibitors such as cutaneous squamous cell cancer, as well as those that are resistant to such agents, as seen in melanoma.